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The linkage between the clinical and laboratory research domains is a key issue in translational research.
Integration of clinicopathologic data alone is a major task given the number of data elements involved.
For a translational research environment, it is critical to make these data usable at the point-of-need.
Individual systems have been developed to meet the needs of particular projects though the need for a
generalizable system has been recognized. Increased use of Electronic Medical Record data in transla-
tional research will demand generalizing the system for integrating clinical data to support the study
of a broad range of human diseases. To ultimately satisfy these needs, we have developed a system to
support multiple translational research projects. This system, the Data Warehouse for Translational
Research (DW4TR), is based on a light-weight, patient-centric modularly-structured clinical data model
and a specimen-centric molecular data model. The temporal relationships of the data are also part of the
model. The data are accessed through an interface composed of an Aggregated Biomedical-Information
Browser (ABB) and an Individual Subject Information Viewer (ISIV) which target general users. The sys-
tem was developed to support a breast cancer translational research program and has been extended to
support a gynecological disease program. Further extensions of the DW4TR are underway. We believe
that the DW4TR will play an important role in translational research across multiple disease types.
 2011 Elsevier Inc. All rights reserved.1. Introduction
Translational research requires integration of clinicopathologic
data, biospecimen data, and molecular data, across multiple data
collection and generation platforms [1–4]. It is also critical to make
these data usable at the point-of-need. From the data management
perspective, clinicopathologic data and molecular data have dis-
tinct features. The former are characterized by a large number of
data ﬁelds, often with missing values due to failure to collect,
non-existence or inaccessibility of the data. Molecular data, on
the other hand, are characterized by a limited number of datall rights reserved.
arch Institute, 620 7th St.,
ton, MA, USA.
e, PA, USA.ﬁelds, large number of records, and ever-evolving data types asso-
ciated with the development of new technologies. While a transla-
tional research project typically collects and generates its own
clinicopathologic and molecular data, public domain data are often
used as well. Furthermore, temporal information needs to be prop-
erly managed and presented.
Many clinical and translational research projects use question-
naires as a clinical data collection instrument, and currently using
data from Electronic Medical Records (EMRs) for translational re-
search is gaining momentum as EMR systems replace paper-based
medical records. Compared to EMRs, questionnaires are simpler as
only questions useful to the speciﬁc research program of the dis-
ease would be included, thus managing such data does not require
a comprehensive system covering all the human diseases. An EMR
system cannot be used as a data management system for transla-
tional research, due to the transactional nature of the former and
the reporting and analysis requirements of the latter. The require-
ments from the US Health Insurance Portability and Accountability
Act of 1996 (HIPAA) for protection of patients’ Protected Health
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translational research may not need all of the data contained in an
EMR and it requires data from other sources as well including
molecular data. It is important that a data centralization system
be developed for translational research capable of inputting clinical
data from questionnaires and EMRs for any human disease, and
integrating molecular data from different biochemical, genomic
and proteomic experimental platforms.
Data warehousing as an important component of biomedical
informatics, provides a way for data integration in clinical and
translational research [2,5–13]. A Data Warehouse (DW) is an
information repository for data analysis and reporting [14,15].
For raw clinical data, an Entity–Attribute–Value (EAV) data model
is often used due to their sparseness and dynamic nature [16–18].
Such data models require the development of ontologies to man-
age the complex relationships between clinical concepts/questions
and possible answers. The user interface is often provided by an
On-Line Analytical Processing (OLAP) tool, which provides multidi-
mensional data analysis capabilities by aggregating data across
hierarchically organized dimensions using either a multidimen-
sional (MOLAP) or relational (ROLAP) model [14,15,19]; the formerrelies on pre-computed data cubes whereas the latter directly que-
ries a relational database.
Developing a comprehensive DW system to meet the needs of
translational research faces many challenges. Based on our own
experience, such challenges include; management of operationally
important information, such as HIPAA compliance and PHI, data in-
put from questionnaires with version control, data input from
EMRs, biospecimen collection and banking, data de-identiﬁcation,
molecular images, multiple-platforms of molecular data, temporal
information, and data ownership, etc. From the system develop-
ment perspective challenges include; development and application
of ontologies including controlled vocabulary and modeling of clin-
ical data, molecular data, image data, and temporal data. In addi-
tion, development of graphical user interfaces for different levels
of users is important, and data security and accessibility should
be properly addressed.
Ontology development is very important to data integration
and exchange; for the purpose of this paper we focus on its phys-
ical artifacts of terminologies/controlled vocabulary and informa-
tion model/data model [20]. Many ontologies have been
developed, each serving a speciﬁc purpose. In the clinical ﬁeld,
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(HL7) for exchange of clinical messages to support clinical practice
and healthcare service [21]; Medical Subject Heading (MeSH) for
medical literature indexing which has also proven useful for clas-
siﬁcation of biomedical entities [22]; Systemized Nomenclature
of Medicine—Clinical Terms (SNOMED-CT), as a comprehensive
clinical healthcare terminology organized hierarchically [23]; and
Digital Imaging Communications in Medicine (DICOM) for medical
image annotations [24]. For biological research, Gene Ontology
(GO), arguably the most successful biological ontology, is aimed
to standardize the representation of gene and gene product attri-
butes across species and databases [25]; Minimum Information
About a Microarray Experiment (MIAME) for microarray-based
technologies is generally accepted by the community [26]; Biolog-
ical Pathway Exchange (BioPAX) is for pathway data exchange [27].
NCI Thesaurus provides reference terminology for many NCI and
other systems covering vocabulary for clinical care and transla-
tional and basic research [28]. Systems have been developed to
unify existing ontologies or provide ontology library services, for
example the BioPortal by the US National Center for Biomedical
Ontology [29], and the Ontology Lookup Service by European
Bioinformatics Institute based on the Open Biomedical Ontology
format [30]. The Uniﬁed Medical Language System (UMLS) devel-
oped by the US National Library of Medicine, aims to provide ad
hoc linkages across life science ontologies [31]. A number of re-
views are available including ones discussing development, imple-
mentation, and use of ontologies [20,32–34].
Temporal information is also very important in modeling health
and disease development. We consider disease as a process, not a
state. Breast cancer, for example, takes many years to develop be-
fore a lesion can be detected by mammography [35]. First consid-
ered by artiﬁcial intelligence researchers in the 1980s, temporal
reasoning and temporal data query became a topic of interest in
biomedical/medical informatics in the 1990s [36–38]. To enable
‘‘controlled language use’’ of the temporal information in health-
care, a European Prestandard CEN ENV 12381 has been developed
[39]. Temporal information needs to be collected, modeled, and
presented. Collection of temporal information can be done explic-
itly through questionnaires or data forms which record historical
information, or abstracted through the time-stamps of data col-
lected and analyzed over time. For the latter, temporal-abstraction
and temporal-querying systems have been developed which have
proven clinically useful in monitoring clinical disorders [40–42].
A data model comprising Parameters, Events, and Constants has
been deﬁned for a temporal query language [43,44], where Param-
eters are basically entities with values bearing a time-stamp,
Events are external acts act upon a patient which could be time-
stamped or occur over a time interval, and Constants are non-tem-
poral measures. There have been reports of a data management or
DW system incorporating temporal information for clinical trials,
time-series gene expression microarray experiment, and medical
information events in a hospital setting [38,45,46].
The many challenges faced in developing a comprehensive DW
system for translational research make this a difﬁcult undertaking.
In practice, different systems have been developed focusing on dif-
ferent challenges based on speciﬁc needs of supported program(s).
For example, I2B2, Informatics for Integrating Biology and the Bed-
side [47], took a top-down ‘‘Enterprise’’ approach with an open
architecture enabling integration of outside modules performing
specialized functions that are needed for translational research
[48,49]. It address a very important and specialized niche in the
clinical informatics space, namely, providing researchers with suf-
ﬁcient access to clinical data to enable study design and cohort
selection, while minimizing many of the patient privacy risks and
concerns [50–54]. A central conundrum of translational research
is that access to detailed clinical data typically requires properinformed consent and IRB approval; however, in order to design
a cohort study or to determine if a particular project is even feasi-
ble, a researcher often needs access to aggregate statistics for key
clinical attributes of interest at an early stage of the process. I2B2
overcomes these challenges by enabling researchers to design
and execute queries against a de-identiﬁed data mart that return
only aggregate counts; furthermore, results are subtly obfuscated
to avoid identiﬁcation by more sophisticated combinations of que-
ries. Having been deployed for a number of projects across multi-
ple sites, I2B2 is a mature software offering. However, it does not
currently provide the level of detailed analysis necessary for clini-
cal and translational research beyond cohort selection and study
design [51–54]. STRIDE, The Stanford Translational Research Inte-
grated Database Environment [55], focuses on a Clinical Data
Warehouse (CDW) and supports a virtual biospecimen model for
accessing several specialized tissue banks [13,56,57]. It also has a
Research Database management system supporting multiple logi-
cally separate research databases. An EAV model is used for data
storage and HL7 Reference Information Model is used for data rep-
resentation. Its semantic layer consists of a framework supporting
multiple terminologies. Some of the Clinical and Translational Sci-
ence Award (CTSA) centers [61] also have data warehousing
efforts.
There are also data warehousing efforts in the cancer Biomedical
Informatics Grids (caBIG) [62]. caBIG is an information network
enabling members of the cancer community to share data and
knowledge based on a core Grid architecture. It was launched in
2003 by the NCI Center for Bioinformatics (NCICB) of the US NIH
[63,64]. One of its datawarehousing efforts is caBIO, amajor compo-
nent of caCORE (cancer Common Ontological Reference Environ-
ment) that was developed before the launch of caBIG [65],
enabling access of biomedical annotations from curated data
sources in an integrated view. As one of the released products of
caBIG, the current version caCORE 3.x includes Enterprise Vocabu-
lary Services for hosting and managing vocabulary, cancer Data
Standards Registry and Repository (caDSR) for hosting and manag-
ing metadata, and the caCORE Software Development Kit [66].
Another data warehousing approach for caGrid is a semantic web-
based data warehouse for creating relationships among caGrid
models, accomplished through the transformation of semanti-
cally-annotated caBIGUniﬁedModeling Language (UML) informa-
tion models into Web Ontology Language (OWL) ontologies that
preserve those semantics [67]. Still another caBIG effort, caIntegra-
tor [58], is a framework for data integration currently capable of
integrating microarray data in caArray and imaging data from the
National Biomedical Imaging Archive (NBIA). It has been applied
to several projects, e.g., REMBRANDT [59] and CGEMS [60]. These
efforts are best described as development projects using the caInte-
grator framework. None of these efforts in caBIG, however, enables
users to dynamically interrogate the clinicopathologic data in a
multidimensional manner by non-informatics specialists using an
intuitive interface.
We began our DW development focused on a questionnaire-
based system, but later realized that a patient-centric and expand-
able data model would be a better solution. We envisioned devel-
oping a system to support translational research in general and
began by developing a system to support the Clinical Breast Care
Project (CBCP) [68] but designed it to be expandable to support
additional programs. This approach has been validated by our suc-
cessful expansion of the system to support a second translational
research program, the Gynecological Disease Program (GDP) [69].
It is currently under further expansion to support a third transla-
tional research program, a consortium effort headed by Thomas
Jefferson University involving ﬁve organizations which is charac-
terizing a set of 5000 invasive breast cancer cases. All these pro-
jects have multiple platforms for clinical and molecular studies.
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tional Research (DW4TR), focused on three challenges in DW
development. The ﬁrst was the development of a pragmatic data
model to satisfy the needs of questionnaire-based clinical data in-
put. Despite the existence of a large number of clinical and biolog-
ical ontologies, there are often gaps, in supporting a research
project, between the available ontologies and the speciﬁc project
needs [70,71]. Many groups therefore create their own ontologies
[72,73]. Given the characteristics of clinical and molecular data,
it is more challenging to develop a general and ﬂexible system
for clinical data; therefore we have made this our ﬁrst priority
[9]. In our case, both CBCP and GDP utilizes not only data elements
covered by existing ontologies, but also detailed and speciﬁc data
elements that are currently not covered. Comparing what we need
to what is available, we concluded that completely adopting one or
two existing ontologies for our DW development is not feasible (c.f.
Section 5). Therefore, we developed our own framework ontology
but referred to existing ones, to satisfy our immediate needs ﬁrst,
planning to map our ontology to existing ontologies at a later time
to enable transportability.
The second challenge, we focused on was interface develop-
ment. A user-friendly interface tailored to the non-informatics spe-
cialist is needed to ensure both the utility and adoption of this
system. The interface that we developed is composed of an Aggre-
gated Biomedical-Information Browser (ABB) and an Individual
Subject Information Viewer (ISIV). ABB is ROLAP-based, thus all
the calculations and queries are performed at the time of use
rather than relying on a pre-calculated data cube, enabling clini-
cians and scientists who are not informatics experts to dynamically
interrogate any combination of the myriad of data elements stored
in the DW4TR. The third challenge we focused on was the manage-
ment of temporal information. We deﬁned three temporal data
types and applied them to data attributes to enable the use of
the temporal information in the DW4TR from both interfaces. In
addition to focusing on these three challenges, we also addressed
a number of other challenges described earlier. For example, in
managing de-identiﬁed clinical information of CBCP and GDP, we
developed solutions to satisfy different requirements for data secu-
rity and accessibility that is also described.2. Methods
2.1. System design and development
Initially developed to support the immediate needs of managing
the clinical, biospecimen, and molecular data for the CBCP, our
design of the DW4TR to be ﬂexible and extensible enabled subse-
quent expansion to support GDP. Both programs use questionnaires
for collecting clinicopathologic information, making expansion of
the light-weight production system straight forward.
2.1.1. The data model
The EAV model is used for the original raw clinical data which
are subsequently hosted in the DW in an extensible data model
reﬂecting the ontology, where the relationships among the attri-
butes are presented in a meaningful way to the users through a
hierarchical organization. The extensible data model is currently
composed of the following components:
2.1.1.1. Patient-centric clinical data model. The clinical data model
was developed to reﬂect the physician–patient interaction. The
ontology framework was developed by a multi-disciplinary team
composed of research physicians, biomedical informaticians, IT
developers, surgeons, pathologists, and gynecologists and was
based on the standard clinical workﬂows and clinical experiences.The development not only referred to existing standards and ontol-
ogies mainly MeSH and SNOMED-CT but also to the NCI Thesaurus
and caBIG VCDE [22,23,28,74], reﬂecting other reported methods
and efforts [32,33,75]. This ontology is reﬂected on the physical
data model, which is hierarchical and composed of a number of
primary modules, e.g., ‘‘Diagnostic’’, which are made up of second-
ary modules (e.g., ‘‘Biopsy’’) and attributes. A secondary module is
further composed of tertiary modules and attributes, and so on. An
attribute is a ﬁne-grained object that is composed of the name, the
data type, and the temporal characteristics (see below). A simple
attribute is often called a data element, e.g., sex. A complex attri-
bute is composed of multiple facets, e.g., exercise is composed of
frequency, intensity, duration, and type. This way, each data ele-
ment of a study is represented in the model either by an attribute
or by a sub-module. The sub-modules are structured hierarchically
to reﬂect the ontology.
2.1.1.2. Specimen-centric molecular study data model. Molecular
(biochemical, genomic and proteomic) analysis are performed on
collected specimens using multiple experimental platforms. Every
experiment is done using biospecimens, including body ﬂuids,
solid tissues, and their derivatives. Thus, a specimen-centric data
model is a natural choice for these types of data, which are con-
nected to the clinical data model hierarchy as a series of sub-mod-
ules. We initially focused on immunohistochemistry (IHC),
Fluorescence In Situ Hybridization (FISH), and gene expression
microarray data and adopted existing clinical or molecular data
standards and guidelines [26,76,77]. The storage and retrieval of
high throughput molecular data poses a number of IT challenges.
A result ﬁle from a single microarray can be tens of megabytes,
and it is not uncommon for a single experiment to make use of
hundreds of such arrays. Common approaches for handling this
type of data include: organizing output ﬁles into a hierarchical ﬁle
system, loading of raw or partially transformed data into a DW, or a
hybrid approach of maintaining certain metadata in a database but
referring back to original output ﬁles with ﬁle pointers. Given the
large number of molecular modalities used in our current and fu-
ture research, no single method was considered suitable, therefore
our system was designed to take an ‘‘all of the above approach’’
that makes use of ﬂexible data processing pipelines. With this ap-
proach distinct pipelines can be created across or even within as-
say types and all of the storage methods discussed above can be
supported. This approach has enabled us to optimize storage of
each assay group individually, as well as provide a mechanism
for handling changing technology and legacy data.
2.1.1.3. Temporal data model. Critical to human disease studies is
the proper representation of temporal information. We deﬁne
three types of temporal data; (1) Static, which is data with no tem-
poral dimension, e.g., ethnicity. (2) Event, which is associated with
a speciﬁc time point, e.g., a surgical procedure. (3) Interval, which
is associated with a starting and ending time point, e.g., a course of
medication. Each attribute in the data model is tagged with a prop-
er temporal status and populated with proper values for temporal
information representation and analysis.
2.1.1.4. Medical image data model. Medical imaging is an important
part of clinical practice and a source of data for various studies. We
initially focus on digitized and digital mammograms, which fol-
lows the DICOM standards [24] and we de-identiﬁed the images
using DICOM Anonymizer Pro. The data ﬁles associated with these
images are large and they impose a challenge in data management,
e.g., storing those image ﬁles in the database of the DW will dras-
tically impede the system performance. Besides, analyzing images
typically requires specialized software. Thus, in the DW4TR, we
store the image ﬁles on a ﬁle server; the ﬁle locations are then
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tions and a thumb nail of the image are also stored in the database
to enable efﬁcient search of relevant features. We intend to apply
the same principle to other images.
2.1.1.5. Relationships between questionnaires and the data
model. The data for both CBCP and GDP studies are collected using
questionnaires each having multiple questions. Each question has
one or more data elements. The data elements could contain values
and temporal information. If a data element contains a value, it is
mapped to an attribute(s). Some questions ask about the same
event at different time points, and these questions are mapped to
the same attribute with corresponding temporal information.
There are also different questionnaires collecting the same infor-
mation, e.g. for different studies, and they have been mapped to
the same attributes as well. Finally each attribute is mapped to
the data model as described above.
2.1.2. User interface development
The requirement to develop an intuitive, user friendly system
that could be used directly by clinicians and researchers as op-
posed to being a specialist tool useful only to the technically savvy,
led to our decision to take the dimensional modeling approach.
While traditional query interfaces are considered intuitive by IT
professionals, we found that the dimensional modeling approach
was generally preferred by our target demographic. A number of
criteria were considered in designing the physical data structure
to support the clinical data warehouse, the ﬁrst of which was the
ability to handle a large number of dimensions. A custom binning
capability that is convenient to use, was an important feature re-
quested by the users. As is the case with any longitudinal study,
the temporal dimension of data is critical, and therefore proper
handling of the temporal dimension was another important con-
cern. Efﬁcient handling of sparsely distributed data and support
for multiple terminology sets were also important criteria. During
such comprehensive communications with the end users, we con-
cluded that all the desired analyses could be categorized as either
an aggregate data analysis or an individualized data analysis. Thus,
we designed a ROLAP-based ABB for the former, and an ISIV for the
latter.
2.2. Implementation
2.2.1. Development environment
Two DELL Windows server systems, one for the application and
the other for the database, were used. Both servers have two Quad
Core Intel Xeron processors and 8 GB RAM. The database server
hard drive is 1 TB and for the application server 0.5 TB, both are in
the RAID 5 conﬁguration. Development is based on the Oracle
RDBMS 10 g, using the InforSense platform that enables a series
of analyses to be performed in an analytical workﬂow environment
with each analysis step represented as a node in the workﬂow [78].
The user-interface is Java based and web accessible. The produc-
tion system has the same conﬁguration. The DW4TR also supports
a one-server system conﬁguration.
2.2.2. Data model and interface implementation
Our physical data model is composed of two distinct elements,
an attribute repository, and an attribute ontology. The attribute
repository stores data in the EAV model. The attribute ontology
is a separate hierarchical data model capturing and providing
structure to the relationships among the attributes that have been
collected so that the ontology (logical patient-centric or specimen-
centric data model) are physically positioned in a hierarchical
organization of attributes for presentation in a meaningful way
to the users of the system.In implementing the data model, ﬁrst the source questionnaires
are reviewed and a logical mapping of the data attributes onto the
newly designed patient modules is developed. This process re-
quires the deﬁnition of the data variable type and other metadata
for different data attributes, and often requires splitting or merging
data elements in order to accommodate the difference in require-
ments of capturing the data versus analyzing the data.
Parallel to the development of the physical and logical data
model was the development of the end user interfaces. Our system
provides users with two distinct applications: the ABB, and the ISIV.
These Java tools are entirely web based with zero client side foot
print, and do not require any additional browser plug-ins. They
provide users with a highly interactive and dynamic experience,
making use of Asynchronous JavaScript and XML (AJAX) techniques
for asynchronous rendering and updating. Both tools are deployed
within the InforSense web portal environment, which provides
the services used for data source connection pooling, user authenti-
cation and authorization, as well as web session management.2.2.3. Data loading
Multiple sources of data in different format are loaded into the
DW4TR, including direct Oracle-to-Oracle load from the Laboratory
Information Management System (LIMS) and ﬂat ﬁles [12,79]. Data
loading is performed through a standard process referred to as Ex-
tract, Transform, and Load (ETL) [14,15].2.3. Data sources
The current DW4TR is host to clinical data from CBCP and GDP.
Subjects are enrolled into the programs via HIPAA compliant, Insti-
tutional Review Board (IRB) approved protocols at multiple partic-
ipating clinical sites, and these protocols explicitly speciﬁedWRI as
the data integration center for the programs. Clinical data are col-
lected through multiple questionnaires, and biological specimens
are collected, processed, banked, and analyzed using genomic
and proteomic experimental technologies.
CBCP and GDP happen to be two distinct types of programs in
administrative structure, clinical dataset, and tissue banking. They
have different data security and access requirements, commanding
distinct solutions in the DW4TR. CBCP is a centralized program
using one set of the questionnaires, one LIMS, one Tissue Bank,
and one data warehouse (the DW4TR). All the participating organi-
zations use approved master IRB protocols from the Walter Reed
Army Medical Center (WRAMC), with minor adaptations to the
requirements of the local institution for local IRB approval, which
is subsequently approved by the IRB of the US Army Medical Re-
search and Materiel Command that contracted the Henry Jackson
Foundation to manage the CBCP. Proper paperwork was done to
enable centralized tissue banking and data warehousing at WRI.
The IRB approved questionnaires contain certain date information
such as date of birth which patients are consented to, thus the
CBCP clinical data is a ‘‘Limited Data Set’’ per HIPAA deﬁnition.
The clinical data and biospecimens are de-identiﬁed, and each sub-
ject is represented by a CBCP number. The link table is securely
maintained at the ofﬁce of the CBCP site PI which is strictly acces-
sible only to the PI or his/her designee at that site. When clinical
data Quality Assurance (QA) problems are identiﬁed in any partic-
ipating institutions, they are all reported to WRAMC and the
WRAMC clinical data team coordinates the QA resolving process.
As of February 2011, over 5000 subjects have been enrolled in
the study using two major questionnaires to collect up to 799
elements of clinicopathology data per subject. More than 43,000
specimens (including aliquots) have been collected and genomic
and proteomic experiments have been conducted using these
specimens.
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nine clinical and research organizations with WRAMC serving as
the lead institution. Each participating organization follows its
own IRB-approved protocol allowing only ‘‘Safe Harbor Data Set’’,
and each site manages and owns its own questionnaire-speciﬁc
datasets. All the captured data are in a de-identiﬁed form, and each
subject is represented by a GDP study ID. Each site PI maintains the
link key to the identity of the subject enrolled at that site. All the
de-identiﬁed data are then sent to WRI, and eventually loaded into
the DW4TR. Aggregated subject information can be shared across
the consortium members, but the detailed individual subject infor-
mation in the DW4TR is only accessible to the originating clinical
site. In GDP, about 500 subjects have been enrolled in the study.
A dozen questionnaires were used to collect more than 7600 ele-
ments of data focusing on surgical procedures, pathology, family
history, psychology, food intake, etc. Currently GDP is consolidat-
ing the questionnaires being used reducing the data elements to
less than 1400.Encounter 
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Fig. 1. Illustration in a 3-dimensional diagram of the relationship between clinical
data (vertical axis), molecular data (horizontal axis), and temporal information (axis
pointing into the page) represented by our data model. The patient is represented
by Patient ID at origin. The three temporal data types are illustrated. This patient
had clinical encounters at four time points, and ‘‘Encounter 1’’ resulted in medical
images and biopsy which led to ‘‘Encounter 2’’, which resulted in biospecimens that
could be used for different types of molecular studies. ‘‘Treatment’’ started from
‘‘Encounter 2’’ and ended at ‘‘Encounter 4’’.
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3.1. Overview of the DW4TR and the relationships between involved
data types
Key to the development of the DW4TR is the understanding of
the complex relationships between data collected or generated
with multiple platforms. Fig. 1 illustrates our understanding of
such relationships in a 3-dimensional patient data space which
we can use to represent our data models.
Fig. 2 is a conceptual view of the DW4TR, as a hybrid system,
that integrates the data collected or generated by the supported
programs, and federates most of other data needed in the studies.
Blocks with solid lines are the areas already developed or currently
under development, and blocks with dashed lines are areas for fu-
ture development. The whole DW is composed of a data tier, a mid-
dle tier, and an application tier. In the data tier, an extended EAV
model is used for the raw clinical data. The middle tier is based
on a patient-centric, modularly-structured clinical data model
(including a medical image data model), integrating a specimen-
centric molecular data model, and a temporal data model. The clin-
ical and molecular data models are designed to be extensible. The
application tier is composed of the ABB and the ISIV, and other util-
ities. Additional applications will be developed to federate and
present other data needed but not generated by the supported
translational research programs.3.2. The ontology and the extensible data model
As a bottom-up approach, we developed a pragmatic light-
weight ontology using controlled terminology both from existing
ontologies and supplemental ones we developed to support the de-
tailed program needs. The relationships between these terminolo-
gies in the ontology are reﬂected on the physical data models
described below.
The patient-centric clinical data model was developed to reﬂect
the physician-patient interaction. As illustrated in Fig. 3, the model
is composed of six major modules: Medical History, Physical Exam,
Diagnostic, Treatment, Outcome, and Scheduling and Consent.
Each of these modules is composed of attributes and sub-modules;
e.g., the Diagnostic module is composed of Biopsy, Imaging, and 
         Other Applications
Disease Data 
Proteomic Data 
Genomic Data 
e Data Model
red clinical data model 
del/Temporal data model
on
External Data
plication tier (green). The data tier is composed of ‘Internal Data’ generated by the
esearch. The ‘‘Internal Data’’ are integrated, and the ‘‘External Data’’ could be in an
locks: developed or in development; dashed line blocks: future development. (For
the web version of this article.)
Fig. 3. A screenshot of the ontology structure of the patient-centric, modularly-
structured clinical hierarchical data model.
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posed of its sub-modules and attributes. Many of these sub-mod-
ules are disease independent but some are disease speciﬁc. This
modularly structured data model enables us to adapt the system
to support the study of a new disease, by re-using disease indepen-
dent modules, and developing a limited number of new modules
speciﬁc to the new disease. The data model has a hierarchical
structure. Users with domain knowledge can explore this hierar-
chical structure to retrieve needed data elements. Users with less
speciﬁc domain knowledge may not be able to explore this data
model as effectively though they can use the keyword search capa-
bility of the system to identify, for selection, the data elements
containing keywords of interest.
3.2.1. The specimen-centric molecular study data model
The specimen-centric molecular study data model is connected
to the clinical datamodel as sub-modules. For example, CBCP breast
tissues and lymph nodes in different preservation types (e.g., OCT,
FFPE, and FF) are represented by sub-modules of Diagnostic-
Biopsy-Tissue Samples, blood samples and their derivatives (e.g.,
PAXgene tube, plasma, cells, serum, and clots) are represented by
sub-modules of Diagnostic-Lab Tests. Genomic, proteomic, and
other molecular studies are performed with molecular derivatives
of the specimens (e.g. DNA, RNA, and protein) on different experi-
mental platforms, e.g., IHC, FISH, gene expression microarray, SNP
microarray, 2D-DIGE, MS, LC-MS, etc. We have completed the mod-
ules for the IHC and FISH assay data, and a proof-of-principle has
been implemented for gene expression microarrays (c.f. Figs. 4
and 5).
3.2.2. Temporal information deﬁnition and presentation
All attributes are tagged with one of the three deﬁned temporal
properties. All temporal information, including static information,
can be viewed in the ISIV (c.f. Fig. 7). Within the ABB users have
the ability to deﬁne ‘‘time ﬁlters’’ for the different columns in the
display (c.f. Fig. 6).
3.2.3. Example data module deﬁnition
Table 1 is a simpliﬁed illustration of three deﬁned data mod-
ules. Thus, ‘‘Ethnic Group’’ is a simple (single attribute) datamodule allowing multiple values for a given subject, and is ‘‘Static’’.
‘‘Alcohol Use’’ is a complex data module with three facets, and cov-
ers an ‘‘Interval’’. ‘‘Surgical Proc(edure)’’ is a module similar to
‘‘Alcohol Use’’ but is an ‘‘Event’’.
3.3. DW4TR interfaces—ABB and ISIV
3.3.1. ABB
This interface allows the user to analyze the data by dynami-
cally creating a multidimensional pivot view. The rows are categor-
ical data ﬁelds of interest, in a hierarchical structure. The columns
can be data elements of either a numerical or categorical nature, in
a ﬂat or hierarchical structure. Although the view is a two dimen-
sional table, the user can effectively explore data of theoretically
unlimited dimensions by simply building multiple levels of a hier-
archical data structure in both the rows and columns, and expand-
ing them. The number of dimensions (levels of hierarchy) is only
practically limited by the performance of the system (see Section
3.6). Fig. 4 (Panels A and B) shows screenshots of how an ABB view
of ﬁve hierarchical levels was created and used to explore one sub-
class of breast cancer patients among CBCP Caucasian American
subjects, who have triple-negative tumors, i.e., ER (estrogen recep-
tor), PR (progesterone receptor), and HER2 (human epidermal
growth factor receptor 2) negative.
Using the ABB, simple analyses such as mean, standard devia-
tion, counts and percentages can be performed. Views on subject
counts or specimen counts can be created. The results of interest
can be printed, or exported to an Excel spreadsheet for additional
analysis using other specialized software. A subject set of interest
can also be saved as a cohort, for example the triple-negative Cau-
casian American breast cancer group shown in Fig. 4B, and used in
a subsequent study or analyzed with a different application. The
cohort can be analyzed using the ISIV described in the next section,
or rendered to additional complicated analysis that the InforSense
Analytical Workﬂow platform supports (not shown). The cohort
data can also be exported to an Excel spreadsheet for analysis by
specialized software outside of the DW4TR.
ABB offers many other features including a unique custom data
binning capability. Multiple binning methods can be used, either
automatically or manually, to create bins to explore data elements
that contain either numerical or categorical values. For different
studies, a user may need to use the same information in different
ways. As shown in Fig. 4 (Panels C and D), the ethnic group attri-
bute contains more than a dozen different possible values from
CBCP and GDP. If the user wants to concentrate on Caucasians, Afri-
can Americans, and Asian Americans, he/she can create three bins
for them, and place the rest in ‘‘Other’’. A histogram of the binning
can then be viewed. Custom data binning can be done with cate-
gorical data as well as numerical data, and in our practice viewing
histograms helps to adjust the binning strategy to ensure that
there are a sufﬁcient number of records available in each bin.
One type of molecular data can be directly accessed through
ABB is IHC. Fig. 4B shows data for three molecules (ER, PR and
HER2) which are routinely assayed in the CBCP, for which there
are established clinical standards for clinical IHC [76,77]. Two
other molecules, Ki67 and p53, are also routinely assayed though
there are no current clinical standards for these molecules. In CBCP,
all ﬁve molecules are characterized by protein expression assayed
by IHC, and HER2 is further characterized with gene copy number
ratio assessed using FISH as needed. Both IHC and FISH data types
are supported in the production system. The IHC submodule con-
tains Result, Percentage, Intensity, and Staining Pattern for nuclear
proteins (ER and PR) or Result and Score for membrane-bound pro-
teins (HER2). The FISH submodule contains Result and Ratio. Both
submodules belong to ‘‘Pathologic Results’’ of ‘‘Biopsy’’ of ‘‘Diag-
nostic’’ in the data model. Speciﬁc business rules are applied in
Fig. 4. Screenshots of ABB. (A) View construction. The column is ‘Patient Pathology Category’, and the rows are, hierarchically, ‘Study’, ‘3 Ethnic Group’ (binned from ‘Ethnic
Group’ as shown in Panels C and D), ‘ER Result’, ‘PR Result’, and the screen was captured when ‘HER2 by IHC: Result’ was being selected. The inset shows a portion of the data
module where the data element resides. (B) View exploration. Rows of ﬁve levels were explored, and at the end the numbers are shown for triple negative (ER-, PR- and Her2-)
subjects for CBCP Caucasian American in each pathology category. Similar analysis can be done for other ethnic groups. (C) The custom data binning feature. Here a manual
binning option is selected. Bins created are ‘Caucasian American’, ‘African American’, ‘Asian American’, and ‘Other’, with Null defaulted. Available values are in the window of
‘Unassigned Values’, which can be dragged into the bins on the left to complete the binning. (D) Histogram of the binning result, which can be viewed during custom data
binning or at the time of use.
H. Hu et al. / Journal of Biomedical Informatics 44 (2011) 1004–1019 1011the ETL process, for example the ﬁnal HER2 expression result is
determined by IHC Score (0 or 1+ as negative, and 3+ as positive),
but when IHC Score is ambiguous (2+) the Ratio of the FISH assay is
used, with 61.8 as negative andP2.2 as positive, and an interme-
diate ratio is considered as ambiguous.A proof-of-principle model of microarray-based molecular data
is in our test system; this feature is the only feature described in
Section 3 that has not yet been applied to the production system.
The MIAME standards [26] are followed with some modiﬁcation,
for example, our ‘‘sample ID’’ eliminates the need for subject and
Fig. 4 (continued)
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ple ID, bio-molecule information (lab protocol, 260/280 ratio, RIN,
etc.), array information (platform, array ID/batch number, etc.),
experimental information (project name, PI, lab operator, date,
etc.), and results (call rate, 30/50 ratio, Pass/Fail ﬂag, data ﬁle loca-
tion, etc.). Metadata are accessible via ABB for selecting micro-
array data of interest in a cohort deﬁned by clinicopathologic
characteristics, but we saved the array raw data ﬁles in a ﬁle ser-
ver due to their size and the fact that their analysis typically re-
quires specialized software that read in the raw data ﬁle directly.
Fig. 5 shows an example how a set of microarray data can be
identiﬁed from previous experiments performed on samples froma cohort of interest. This information may lead to a secondary use
of the microarray data, or help the researcher to design a new
experiment.
ABB also contains a utility ‘‘Time Filter’’ to apply temporal infor-
mation in the analysis of aggregated information. The time ﬁlters
are used to limit or constrain the data that are returned much like
any other type of ﬁlter criteria. Time ﬁlters can be created based on
absolute dates, patient age, or relative to other events. Fig. 6 shows
one example how ‘‘Alcohol Usage’’ was analyzed for CBCP subjects
when they were at different age ranges. ‘‘Alcohol Usage’’ is an
Interval temporal data type with values self-reported by subjects
covering different periods of time in patient’s life. Note that direct
Fig. 5. Screenshot of ABB showing exploration of available gene expression microarray data on biospecimens of a CBCP cohort of interest. Subjects were Caucasian American,
post-menopausal or pre-menopausal, and experiments were performed on an Affymetrix platform. Subjects were mostly invasive breast cancer patients and normal subjects
(as represented by ‘Value Not Set’ in the last column). The numbers from each pathology category do not completely add up to the total patient count on the left-most column
since a couple of patients changed the category status with time. Highlighted row of subjects (light blue) can be saved as a cohort for further studies.
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analysis.
3.3.2. ISIV
This interface is for viewing and analysis of detailed subject
information, most importantly the temporal-related information.
It takes subject IDs as the input either by direct entry, or selecting
from a pre-deﬁned cohort. Events and Intervals of interest can be
selected, and applied to the whole subject set. Information can
be viewed independently for every subject, or aligned across the
subject set on Events of interest to enable comparison between
subjects. Static information can be displayed as well, so all the
information about the subject can be studied. An example screen-
shot of ISIV is shown in Fig. 7.
Both the ABB and ISIV require minimal training before one can
start to use them. The average training time for a clinician or scien-
tist is 15 min, and the user can learn more features by using the
system. Interestingly, for a high school student the average training
time is only 10 min.
3.4. Direct data extraction from the database
The raw data in the DW4TR can be directly queried from the
database, as a complete or partial dataset depending on the re-
search need. The data can be presented in either a ﬂat ﬁle structure
or in Excel spreadsheet, for use with specialized data analysis soft-
ware such as SAS, SPSS, or R. Such queries have been developed for
and applied to both CBCP and GDP data. Direct data extraction re-
quires a database administrator and is not the focus of this paper,
thus is only brieﬂy described here.3.5. Extensibility of the DW4TR
The DW4TR was developed to support the CBCP with a vision to
support translational research in general. This extensibility was
tested and validated by expanding the system to support the
GDP. Its ﬂexibility was tested by our successful revision of the
model commanded by the consolidation of GDP questionnaires
and data elements. A number of disease-independent attributes
and submodules developed for the CBCP implementation were
re-used for the GDP instance, for example demographics and ele-
ments of past medical history. Many other attributes/submodules
were modiﬁed to satisfy the requirements of GDP, for example
alcohol usage. For GDP-speciﬁc data elements, additional modules
were developed. In addition, the GDP contains a psychology ques-
tionnaire and a food questionnaire that are program-speciﬁc but
not disease-speciﬁc. These were developed and structured to the
overall patient-centric clinical data model, and could potentially
be re-used for future programs. In addition, the GDP has different
data security and accessibility requirements, and we have devel-
oped additional mechanism for it as detailed in Section 4. With
the experience gained in supporting the GDP, we are conﬁdent that
we will succeed in the current further extension of the system to
support the third translational research program for the consor-
tium led by Thomas Jefferson University.
3.6. System performance
To evaluate the performance potential of the DW4TR, we con-
ducted a stress test using the CBCP data in a one-server system
conﬁguration. The test was done from a user’s perspective, by
Fig. 6. Use of temporal information in ABB to study data of interests. (A) Screenshot showing the use of the ‘Time Filter’ to deﬁne the starting and ending time for study, with
starting time already being conﬁgured but not the ending time. (B) Conﬁguring the ending time based on Age, but it can also be based on Absolute Date or an Attribute. (C)
Example showing the alcohol usage history across the CBCP subjects. The ﬁrst column shows the usage frequencies of subjects when they were between 18–25 years of age,
and the second column shows the usage frequencies across the whole population. Additional age ranges can be conﬁgured to show the corresponding alcohol usage habit.
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hierarchical view for the ﬁrst time—note that subsequent display
of the same data is much faster. The view is composed of three
levels of Pathology Category, Ethnicity, and Body-Mass Index
(BMI, with custom-binning) in the rows and record counts in the
columns. Starting from the then patient number of 4234, we artiﬁ-
cially replicated the records in the database to 8468, 16,936,
33,872, and 67,744 without performing a database tune-up other
than Oracle table analysis. It took one second or less, for the level1 (Pathology Category) and level 2 (Ethnicity) data to be displayed
in all these tests. For level 3 (BMI), it took 2, 4, 12, 39, and 134 s
respectively to display the data when the number of records dou-
bled stepwise from 4234 to 67,744. Given that the current CBCP
annual subject enrollment is about 600, it will take another
20 years before 16,936 subjects are enrolled when 12 s are needed
to display 3 levels of data. We expect that the system performance
will be further dramatically improved with hardware upgrades and
Oracle tuning.
Table 1
Example data module deﬁnition.
ID Attribute Facet Data type Units Multiple values From date To date Temporal information Parent ID
23 Ethnic Group VARCHAR2 Yes Static
103 Alcohol Use COMPLEX No mm/dd/yyyy mm/dd/yyyy Interval
104 Alcohol Use Name VARCHAR2 No mm/dd/yyyy mm/dd/yyyy Interval 103
105 Alcohol Use Frequency NUMBER /day No mm/dd/yyyy mm/dd/yyyy Interval 103
106 Alcohol Use Amount NUMBER drinks No mm/dd/yyyy mm/dd/yyyy Interval 103
1541 Surgical Proc COMPLEX No mm/dd/yyyy Event
1542 Surgical Proc Name VARCHAR2 No mm/dd/yyyy Event 1541
1543 Surgical Proc Code VARCHAR2 No mm/dd/yyyy Event 1541
1544 Surgical Proc Laterality VARCHAR2 No mm/dd/yyyy Event 1541
Fig. 7. Screenshot of the ISIV. Temporal information from three subjects is shown. Users can zoom in or out, align the information on a speciﬁc event for cross-subject
comparison, and explore more detailed information by clicking on the event of interest. The temporal axis shows the age but can be toggled to calendar year.
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The DW4TR has been playing an important role in supporting
translational research across user groups in both WRI and WRAMC.
Here we report four example use cases to demonstrate the utility
of the system.
3.7.1. The DW4TR enables clinicians to study the integrated data
directly
When ﬁrst exposed to the DW4TR, CBCP clinical users appreci-
ated the simple interface which gave them their ﬁrst opportunity
to directly study the integrated clinicopathologic and biospecimen
data. They were happy to see that the results shown on the ABB
conﬁrmed their qualitative clinical observations. In one short ses-
sion of less than 1 h, the program PI identiﬁed several lines of evi-
dence which subsequently led to an abstract accepted to the San
Antonio Breast Cancer Symposiums [80]. The system has sincebeen further improved in both the data model structure and the
user interface.
3.7.2. The DW4TR enables enhanced cohort and biospecimen selection
Before the DW4TR was developed, cohort and biospecimen
selection for any research project was a major task involving multi-
ple data sources including: Core Questionnaires, Pathology Check-
lists, and IHC assay reports, in the form of an Oracle database, a
Microsoft Access database, Excel spreadsheets, and occasionally
hard copy reports. Many manual steps were involved, and the pro-
cedure was not standardized. The selection of biospecimens was
especially challenging when there were temporal restrictions, for
example identifying blood samples drawn in a subject cohort before
certain kinds of invasive procedures were performed. This require-
ment alone could take an experienced researcher several days since
multiple questionnaires are involved and a number of surgical pro-
cedures could be performed on one subject and that there were 15
Table 2
Example classiﬁcations of breast neoplasms in MeSH, SNOMED, and DW4TR.
Name Classiﬁcations
MeSH1 3. Diseases (C)? Skin and Connective Tissue Diseases [C17]? Skin Diseases [C17.800]? Breast Diseases [C17.800.090]? Breast Neoplasms
[C17.800.090.500]
MeSH2 3. Diseases (C)? Neoplasms [C04]? Neoplasms by Site [C04.588]? Breast Neoplasms [C04.588.180]
SNOMED1 SNOMED CT Concept (SNOMED RT + CTV3)? Clinical ﬁnding (ﬁnding)? Disease (disorder)? Disorder by body site (disorder)? Disorder of body system
(disorder)? Disorder of breast (disorder)? Neoplasm of breast (disorder)
SNOMED2 SNOMED CT Concept (SNOMED RT + CTV3)? Clinical ﬁnding (ﬁnding)? Finding by site (ﬁnding)? Finding of body region (ﬁnding)? Finding of trunk
structure (ﬁnding)? Finding of region of thorax (ﬁnding)? Breast ﬁnding (ﬁnding)? Disorder of breast (disorder)? Neoplasm of breast (disorder)
DW4TR Medical History? Past Medical History?Major Adult Illnesses? Breast Cancer
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additional utilities, the time needed to perform such tasks has now
been reduced to minutes. Currently any cohort and biospecimen
selection can be done in hours instead of days or weeks.
3.7.3. The DW4TR serves as a research environment for risk factor
assessment
The DW4TR provides an effective research environment for can-
cer risk factor analysis. Several studies examining breast cancer
risk factors have been done using this system [81–85], and several
new studies are underway.
3.7.4. The DW4TR facilitates virtual experimental studies
Virtual experimental studies can be performed as integrated
information associated with completed research projects is avail-
able. Using the information stored in the DW4TR and the ﬁle ser-
ver, we identiﬁed the gene expression microarray data from
three previous projects, on two types of specimens from three sub-
ject groups. From these datasets we were able to create two virtual
experiments, and both studies were accepted to leading scientiﬁc
conferences [86,87].4. Security and accessibility
Data security and access control are important factors in the de-
sign of the DW4TR, particularly as our system can be expanded to
include multiple research studies. The use of clinical data in trans-
lational research is governed by HIPAA compliant IRB approved
protocols, and typically cannot be unconditionally shared. Thus
we have designed and developed a set of data security and access
solutions to satisfy such requirements.
The ﬁrst layer of security for the system is data de-identiﬁca-
tion. Prior to being loaded into the DW4TR, PHI is stripped away
from the collected data. At this point subjects will have been as-
signed a unique research subject ID for linking together subject
information across multiple sources. The next level of security
makes use of the ‘‘Virtual Private Database’’ (VPD) feature of Ora-
cle, which allows for row level access control within the DW.While
one of the strengths of the system is the ability to perform cross-
study analysis, in many instances it is necessary to restrict data vis-
ibility among different users of the system. In our security model,
all users are assigned roles which dictate the data they are permit-
ted to access. The VPD system is designed such that every data ele-
ment in the DW is tagged with a study identiﬁer that is associated
with the different user roles, enabling data access control. The third
level of security is at the application tier. All access to the DW oc-
curs through a password protected web portal that is served by an
application server. The ﬁnal layer of security is a network ﬁrewall
and Virtual Private Network (VPN) for which the 168-bit encryp-
tion Secure Sockets Layer VPN from Juniper Networks Inc. is de-
ployed. All components of the system, including the DW4TR and
the web portal, are protected behind the local network ﬁrewall
and are only accessible from either within the Institute itself, or
by ﬁrst establishing a VPN connection to the network.These security and access control measures were developed
based on the needs of the supported programs, and can be selec-
tively applied to individual programs. For the two programs
currently supported by the DW4TR, CBCP protocols allow data ac-
cess by all CBCP researchers, and VPN access to the DW4TR is
granted with written permission of the CBCP program PI. For
GDP, aggregated biomedical information is allowed for use by all
the GDP researchers, but the detailed subject information is only
allowed to the originating clinical sites unless additional paper-
work is completed. Thus, we have designed and developed a
role-based site-speciﬁc privilege system to enable GDP users to
use ABB and the ISIV. DW4TR can also be conﬁgured to disable
functions and utilities of choice. Currently at the request of the
GDP PI, we have disabled the ISIV functions for GDP users so that
the GDP data are only available through ABB to GDP users for
aggregated information. When a GDP researcher identiﬁes a cohort
of interest, additional data use agreements will be completed to re-
quest individual subjects’ information from the corresponding clin-
ical sites, for approval by the involved sites and the GDP program
PI. With a written request from the GDP program PI, WRI will sup-
ply the detailed data from the DW4TR to the researcher.5. Discussion
We have taken a bottom-up approach to develop a DW4TR to
support translational research programs. The system is extensible,
integrating internally generated clinicopathologic and molecular
data based on a light-weight ontology, with a patient-centric, mod-
ularly structured clinical data model supplemented with a speci-
men-centric molecular data model. Two interfaces have been
developed targeting non-informatician end users, with the ABB
supporting aggregated data analysis and ISIV supporting single
subject information analysis. The system enables study cohort
and biospecimen selection and is capable of handling temporal
relationships between clinical data and biospecimen data collected
at multiple points in time.
The development of our data model relies on using or creating
ontologies for clinical and molecular data types. We will focus this
discussion on clinical data ontology. In fact, for molecular data
types, the scale of work is much smaller and the existing ontologies
are mostly adequate. For example, we found that the MIAME stan-
dard met our needs for modeling gene expression microarray
metadata. Our analysis indicated that existing ontologies for clini-
cal data cannot be readily adapted to satisfy our speciﬁc research
needs, due to gaps between existing ontologies and our needs as
well as overlaps and inconsistencies between existing standards
and ontologies [70,71]. For example, the CBCP Pathology Checklist
contains 372 data elements including 131 breast pathology condi-
tions. When the data form was developed and revised, the AJCC
(American Joint Committee on Cancer) guidelines and ASCO/CAP
(American Society of Clinical Oncology/College of American Pathol-
ogists) guidelines were followed; these guidelines, like many other
guidelines, have evolved over the years [88–91]. Many data ele-
ments present in the CBCP lack standard descriptions, for example
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and p53) do not even have a standard clinical IHC protocol. There-
fore, descriptions or deﬁnitions of such data elements were devel-
oped based on medical textbooks and pathologist’s clinical practice
for the Pathology Checklist, which we modeled ourselves.
There are classiﬁcations in existing standards/ontologies that
we ﬁnd cumbersome or which do not meet our needs [92]. We
show as an example in Table 2 the classiﬁcations of ‘‘Breast Neo-
plasms’’ by two existing ontologies. In MeSH, it is classiﬁed under
‘‘Skin Diseases’’. This classiﬁcation (named ‘‘MeSH1’’ in Table 2) is
not available in the SNOMED-CT classiﬁcations under either Skin
Diseases or Connective Tissue Diseases. In MeSH, ‘‘Breast Neo-
plasms’’ is also classiﬁed under ‘‘Neoplasms’’ (in a way we agree
with, ‘‘MeSH2’’ in Table 2). However, in the two classiﬁcations,
‘‘Breast Neoplasms’’ have different codes, which may cause a prob-
lem in the practical applications of data modeling. In SNOMED-CT,
the term ‘‘Neoplasm of Breast’’ is used, and there are several clas-
siﬁcations leading to it with relatively long paths. We show two of
them, ‘‘SNOMED1’’ and ‘‘SNOMED2’’ in Table 2. In our pragmatic
approach to support the CBCP, applying such a complete classiﬁca-
tion is cumbersome. In addition, reconciliation of discrepancies
among the available ontologies and our understanding of the prob-
lem, for all the data elements in the CBCP, is a major task and not
one of our immediate project needs. Therefore, we have developed
a classiﬁcation path for ‘‘Breast Cancer’’, which is more light-
weight but adequate to our needs (see ‘‘DW4TR’’ in Table 2).
Finally, some questions in the questionnaires of the two pro-
grams we currently support do not comply with existing standards,
but we are still required to model them to enable proper storage
and presentation of the data. Such problems have been reported
to program PIs and were taken into consideration, for example in
the consolidation of the GDP questionnaires. In addition, existing
ontologies are not static, for example MeSH is currently updated
weekly and SNOMED-CT is updated monthly. Thus, after analyzing
what is available and what we need to support, we determined that
our best approach was to design a light-weight ontology incorpo-
rating existing standards and ontologies where possible and to
map our classiﬁcation system to existing ones at a later time. The
mapping table(s) will serve as the buffer between the two moving
targets which will ensure transportability and un-interrupted use
of the system. We will also supplement those standards with new
ontologies and common data elements that we deﬁne.
The DW4TR currently supports limited number of molecular
data types and we will continue to develop data models to support
other molecular study platforms, including SNP microarray and ar-
ray CGH data. We expect that the method developed for gene
expression microarray will in general be applicable to these ar-
ray-based technologies. We will explore support for RT-PCR, tissue
microarrays, mass spectrometry, and Next Generation sequencing
technologies. These will depend on the needs of the users and pro-
grams that we support.
Currently a prototype has been developed to enable access to
medical and molecular images through the ISIV, including digital/
digitized mammograms and gene expression microarray images.
A thumbnail of the image is stored in the database of the DW with
searchable annotations. The full-size image is stored in a ﬁle server
instead of the DW4TR database for performance considerations.
We plan to follow the DICOM standard for medical images and will
explore how to best annotate molecular images. Additional images
we need to support include, pathology H&E slide images, bio-
marker IHC images, and tissue microarray images. Note that all
the medical images have to be de-identiﬁed for research purpose.
Currently the DW4TR does not support EMR for data input. We
have a stepwise plan to begin using EMR records for CBCP subjects
and we are looking at subject de-identiﬁcation, data extraction,
and data model expansion. Although we do not plan to take asystematic ‘‘Enterprise’’ approach, we will learn from such ap-
proaches as used by I2B2 and others. When EMRs are used as an
input, a number of functions need to be integrated into the system
including subject de-identiﬁcation and information extraction, for
which the I2B2 development teams have made good progresses
[50,54,93]. While I2B2 clearly plays an important role in the study
design phase including addressing de-identiﬁcation and natural
language processing, it was not designed to be a comprehensive
solution that can provide the level of detailed access necessary
for later stage research [50–54]. The ABB described here provides
the same ability to generate aggregate statistics for population
stratiﬁcation and cohort selection, but by doing this in a web-based
pivot table interface it also facilitates trend identiﬁcation and dis-
covery in a way traditional query interfaces cannot. From a data
modeling perspective, the ABB also allows for more sophisticated
handling of complex, multi-faceted attributes whereas I2B2 only
offers aggregation around the single pivot point of the patient.
I2B2 makes good use of ontologies, but has not yet developed an
ontology with the level of detail described here [54,94]. Further-
more, by design I2B2 does not enable access to row level clinical
data and detailed clinical timeline provided by the ISIV [54,94].
In conclusion, we have developed the DW4TR to support a
breast cancer translational research program and then expanded
it to support a gynecological disease translational research pro-
gram. It is based on a light-weight ontology and equipped with
an interface capable of handling temporal information, designed
for use by non-informatician specialists including clinicians and
laboratory scientists. The system supports both in silico and
in vitro studies. With its proven extensibility, we believe that the
DW4TR will play an important role in translational research across
multiple disease studies.Acknowledgments
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